Setrobuvir

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Setrobuvir (ANA598) 是一种口服活性的非核苷 HCV NS5B 聚合酶抑制剂。Setrobuvir 抑制 RNA 的从头合成 (RNA synthesis) 和引物延伸，IC50在 4~5 nM 之间。Setrobuvir 还显示出与 SARS-CoV-2 RdRp 的优异结合亲和力，并诱导 RdRp 抑制。

Setrobuvir (ANA598) is an orally active non-nucleosidic HCV NS5B polymerase inhibitor. ANA-598 inhibits both de novo RNA synthesis and primer extension, with IC50s between 4 and 5 nM. Setrobuvir also shows excellent binding affinity to SARS-CoV-2 RdRp and induces RdRp inhibition.

Setrobuvir (ANA598) is a non-nucleoside inhibitor that binds to the palm pocket of the HCV polymerase and has an EC50 against HCV genotype 1b/Con1-containing subgenomic replicons in the nanomolar range. Setrobuvir appears to inhibit both de novoinitiated RNA synthesis and primer extension, and its activity is unchanged by the presence of mutations that modify the activity of thumb-binding non-nucleoside inhibitors.

——

——

Others

Other Targets

SARS-CoV | DNA/RNA Synthesis | HCV Protease

——

——

1071517-39-9

560.62

C25H25FN4O6S2

>98% (HPLC)

——

C(N1[C@@]2([C@@]([C@@]3(C[C@]2(CC3)[H])[H])(C(O)=C(C1=O)C=4NC=5C(S(=O)(=O)N4)=CC(NS(C)(=O)=O)=CC5)[H])[H])C6=CC=C(F)C=C6

——

(-20℃)

With Ice Pack

≥ 2 years